BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26122937)

  • 1. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening.
    Simão A; Madaleno J; Silva N; Rodrigues F; Caseiro P; Costa JN; Carvalho A
    BMC Gastroenterol; 2015 Jun; 15():73. PubMed ID: 26122937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma.
    Nabih MI; Aref WM; Fathy MM
    Arab J Gastroenterol; 2014; 15(3-4):103-7. PubMed ID: 25249230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma.
    Abu El Makarem MA; Abdel-Aleem A; Ali A; Saber R; Shatat M; Rahem DA; Sayed D
    Ann Hepatol; 2011; 10(3):296-305. PubMed ID: 21677331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma.
    Jang ES; Jeong SH; Kim JW; Choi YS; Leissner P; Brechot C
    PLoS One; 2016; 11(3):e0151069. PubMed ID: 26986465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.
    Vongsuvanh R; van der Poorten D; Iseli T; Strasser SI; McCaughan GW; George J
    PLoS One; 2016; 11(5):e0155800. PubMed ID: 27219517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma.
    Chimparlee N; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Payungporn S; Poovorawan Y; Tangkijvanich P
    Asian Pac J Cancer Prev; 2015; 16(16):7211-7. PubMed ID: 26514514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of osteopontin as a novel marker for early hepatocellular carcinoma.
    Shang S; Plymoth A; Ge S; Feng Z; Rosen HR; Sangrajrang S; Hainaut P; Marrero JA; Beretta L
    Hepatology; 2012 Feb; 55(2):483-90. PubMed ID: 21953299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis.
    Abdel-Hafiz SM; Hamdy HE; Khorshed FM; Aboushousha TS; Safwat G; Saber MA; Seleem M; Soliman AH
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):1021-1027. PubMed ID: 29693976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
    Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
    Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
    BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma.
    Ge T; Shen Q; Wang N; Zhang Y; Ge Z; Chu W; Lv X; Zhao F; Zhao W; Fan J; Qin W
    Med Oncol; 2015 Mar; 32(3):59. PubMed ID: 25652109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis.
    Zhu M; Zheng J; Wu F; Kang B; Liang J; Heskia F; Zhang X; Shan Y
    J Med Virol; 2020 Dec; 92(12):3596-3603. PubMed ID: 32043608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
    Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
    Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
    Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
    PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.
    Duarte-Salles T; Misra S; Stepien M; Plymoth A; Muller D; Overvad K; Olsen A; Tjønneland A; Baglietto L; Severi G; Boutron-Ruault MC; Turzanski-Fortner R; Kaaks R; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Bamia C; Pala V; Palli D; Mattiello A; Tumino R; Naccarati A; Bueno-de-Mesquita HB; Peeters PH; Weiderpass E; Quirós JR; Agudo A; Sánchez-Cantalejo E; Ardanaz E; Gavrila D; Dorronsoro M; Werner M; Hemmingsson O; Ohlsson B; Sjöberg K; Wareham NJ; Khaw KT; Bradbury KE; Gunter MJ; Cross AJ; Riboli E; Jenab M; Hainaut P; Beretta L
    Cancer Prev Res (Phila); 2016 Sep; 9(9):758-65. PubMed ID: 27339170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis.
    Li J; Chen X; Dai M; Huang S; Chen J; Dai S
    Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):543-553. PubMed ID: 28291627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma.
    da Costa AN; Plymoth A; Santos-Silva D; Ortiz-Cuaran S; Camey S; Guilloreau P; Sangrajrang S; Khuhaprema T; Mendy M; Lesi OA; Chang HK; Oh JK; Lee DH; Shin HR; Kirk GD; Merle P; Beretta L; Hainaut P
    Int J Cancer; 2015 Jan; 136(1):172-81. PubMed ID: 24803312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis.
    Khan IM; Gjuka D; Jiao J; Song X; Wang Y; Wang J; Wei P; El-Serag HB; Marrero JA; Beretta L
    Cancer Prev Res (Phila); 2021 Jun; 14(6):667-674. PubMed ID: 33685927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Role of Blood Tumor Markers in Predicting Hepatocellular Carcinoma in Liver Cirrhosis Patients Undergoing Liver Transplantation.
    Kim Y; Park YH; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Lee SG
    Ann Transplant; 2016 Oct; 21():660-667. PubMed ID: 27777395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.